Please enable Javascript
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Myelofibrosis
The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Advertisement
Patient-Centered Approaches in Today’s MF Treatment Paradigm
Pankit Vachhani, MD
Myelofibrosis
|
May 12, 2025
Experts discuss patient-centered approaches and novel therapies reshaping MF treatment in a roundtable.
View More
Future-Ready MF Care: Better Outcomes Through Research
Prithviraj Bose, MD
Myelofibrosis
|
May 12, 2025
Experts explore anemia therapies, JAK inhibitors, and transplant innovations shaping the promising future of MF care.
View More
Tailoring Myelofibrosis Care With the Latest Molecular Discoveries
Naseema Gangat, MBBS
Myelofibrosis
|
May 12, 2025
Experts discuss molecular insights into MF, highlighting mutations, risk assessment, and evolving therapeutic approaches.
View More
The Evolving Role of Targeted Therapy in Myelofibrosis
Prithviraj Bose, MD
Myelofibrosis
|
May 12, 2025
Experts discuss current treatments and ongoing research in myelofibrosis, highlighting new therapies and clinical trials.
View More
Tomorrow’s Myelofibrosis Therapies
Idoroenyi Amanam, MD
Myelofibrosis
|
May 12, 2025
Experts discuss CALR-targeting therapies, symptom assessment, and the future of myelofibrosis treatment and regulation.
View More
The METER Study Provides a Picture of Myelofibrosis Management Trends Worldwide
Andrew Moreno
Myelofibrosis
|
March 28, 2025
Investigators observed that overall treatment has improved but hospitalizations and other events indicate unaddressed need.
Read More
Advertisement
What Is the Prognostic Impact of JAK2V617F VAF and High Molecular Risk Mutations in Myelofibrosis?
Melissa Badamo
Myelofibrosis
|
March 27, 2025
Harboring high molecular risk mutations and a lower JAK2V617F VAF were independent adverse prognostic factors for survival.
Read More
MOMENTUM Study Data Analysis Bolsters Myelofibrosis Symptom Assessment Tool’s Credibility
Andrew Moreno
Myelofibrosis
|
March 27, 2025
The Myelofibrosis Symptom Assessment Form is the only instrument currently available for evaluating myelofibrosis symptoms.
Read More
Can a BET/JAK Inhibitor Combination Break Pathobiological Barriers in Myelofibrosis Treatment?
Nichole Tucker
Myelofibrosis
|
March 25, 2025
According to John O. Mascarenhas, MD, the phase 3 MANIFEST study heralds a new era of combination therapy for myelofibrosis.
Read More
New Trial Data Emerges on Rusfertide for Erythrocytosis Control in Phlebotomy-Dependent PV
Andrew Moreno
Polycythemia Vera
|
March 25, 2025
In a phase 2 trial the hepcidin mimetic increased hematocrit control while reducing phlebotomy and patient-reported symptoms.
Read More
Driver Mutation Clearance After HSCT Associated With Improved Survival, Lower Relapse in Myelofibrosis
Melissa Badamo
Myelofibrosis
|
March 25, 2025
Most patients with JAK2, CALR, and MPL mutations had mutation clearance 100 days after HSCT.
Read More
Status Update: What Is the Current Data on JAK Inhibitors for Myelofibrosis?
Melissa Badamo
Myelofibrosis
|
March 10, 2025
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
Read More
Selinexor in MPNs: Optimizing What's Available
John Mascarenhas, MD
Myelofibrosis
|
February 18, 2025
Discussing the evolving role of selinexor in treatment of myeloproliferative neoplasms.
View More
The Importance of Patient-Centered Treatment in MPNs
John Mascarenhas, MD
Myelofibrosis
|
February 18, 2025
Watch as Viges and Dr. Mascarenhas explore strategies to enhance patient-centered care in MPN management.
View More
Ongoing Research Aims to Fill Gaps in Myelofibrosis Care
John Mascarenhas, MD
Myelofibrosis
|
February 18, 2025
Exploring the latest advancements in myelofibrosis research with Kapila Viges, MD and John Mascarenhas, MD.
View More
Clinical Experts Discuss Momelotinib for Myelofibrosis: Anemia Utility, Dosing, Safety
Prithviraj Bose, MD
Meeting News
|
December 30, 2024
The panel moderated by Prithviraj Bose, MD, goes into detail on practical aspects of this agent's use in the clinic.
View More
Highlights in Myelofibrosis Research at ASH 2024: Momelotinib in Anemic Patients
Prithviraj Bose, MD
Meeting News
|
December 30, 2024
The expert panel moderated by Dr. Bose looks at noteworthy study work on use of this agent for anemia in myelofibrosis.
View More
Highlights in Myelofibrosis Research at ASH 2024: Comparing Momelotinib, Other JAK Inhibitors
Prithviraj Bose, MD
Meeting News
|
December 30, 2024
Empaneled experts describe their investigations of momelotinib in a continued discussion moderated by Prithviraj Bose, MD.
View More
Highlights in Myelofibrosis Research at ASH 2024: Experts’ Selections
Prithviraj Bose, MD
Meeting News
|
December 30, 2024
The expert panel moderated by Prithviraj Bose, MD, tells which research presented at the Meeting they found most exciting.
View More
Expanding Myelofibrosis Treatment: The Role of Momelotinib
Prithviraj Bose, MD
Myelofibrosis
|
December 31, 2024
Esteemed experts provide valuable insights into the evolving myelofibrosis landscape and its implications for patient care.
View More
Load More
Advertisement
Advertisement